Loading organizations...
Embla Medical is an Iceland-based global provider of mobility solutions that develops prosthetics, neuro orthotics, bracing, and specialized patient care services. The publicly traded medical device company is listed on the NASDAQ Copenhagen Stock Exchange and holds an extensive intellectual property portfolio consisting of more than 2,100 patents. Operating across the Americas, Europe, and Asia, the global organization manages a network of patient care clinics and oversees prominent portfolio companies including Össur, Fior and Gentz, and College Park. Its recent acquisition of Fior and Gentz expanded its commercial operations into the $500 million neuro orthotics market. Additionally, its broader accessibility innovations recently earned the enterprise a spot on the Forbes Accessibility 100 list. Embla Medical was originally founded in 1971 by Össur Kristinsson following his initial development of the world's first silicone prosthetic liner.
Embla has raised $4.0M across 1 funding round.
Embla has raised $4.0M in total across 1 funding round.
Embla has raised $4.0M in total across 1 funding round.
Embla's investors include Crowberry Capital.
Embla has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in July 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2022 | $4M Seed | — | Crowberry Capital | Announced |
Embla Medical hf. (EMBLA) is a medical technology company specializing in mobility solutions, including prosthetics, neuro orthotics, bracing and supports, and patient care services through its ForMotion clinic network.[1][3] It builds an integrated portfolio from product innovation to clinical delivery, serving healthcare providers, rehabilitation specialists, and patients globally across the Americas, Europe, and Asia-Pacific, addressing mobility challenges for diverse activity levels and clinical needs.[1][3] The company drives sustainable growth via organic expansion, targeted acquisitions, and operational efficiency, with 4,000 employees and record sales alongside strong EBITDA margins.[1]
Embla Medical hf. originates from the legacy of Össur, a prominent prosthetics leader, consolidating brands like Össur, Fior & Gentz, College Park, and the ForMotion patient care network into an end-to-end mobility ecosystem.[1][3] Key leadership includes CEO Sveinn Solvason, steering operations from Reykjavik, Iceland (despite Danish stock listing).[1] The company's evolution emphasizes multi-year strategies for organic growth and acquisitions, building on established manufacturing and R&D from Össur's heritage, with pivotal integration of global clinics and brands to enhance patient outcomes.[1][3]
(Note: A separate entity, Embla Systems, emerged in the mid-1990s in Colorado, USA, focusing on sleep apnea detection devices for sleep labs and home studies, but lacks connection to Embla Medical's mobility focus.[2])
Embla Medical rides the aging population and mobility tech wave, where rising demand for advanced prosthetics and orthotics aligns with trends in personalized medicine, AI-driven customization, and tele-rehabilitation.[1][3] Timing benefits from post-pandemic healthcare shifts toward efficient, scalable solutions amid global shortages in rehab services. Market forces like increasing chronic conditions (e.g., diabetes-related amputations) and reimbursement expansions favor its integrated model, influencing the orthotics-prosthetics ecosystem by setting standards in clinical evidence, manufacturing scalability, and patient-centric delivery at global scale.[1][3]
Embla Medical is poised for accelerated growth through organic expansion, bolt-on acquisitions, and tech-infused innovations like AI-optimized prosthetics and expanded neuro orthotics.[1][3] Trends such as wearable sensors, 3D-printed customization, and value-based care will shape its trajectory, potentially elevating its influence in medtech via deeper academia partnerships and emerging markets. As mobility solutions evolve into "Life Without Limitations," Embla could redefine end-to-end care, building on its Össur legacy to lead sustainable, patient-focused advancements.[3]
